Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06055504

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)

Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for Sudden Cardiac Death (SCD) prevention in patients with non-ischemic dilated cardiomyopathy with Left Ventricular Ejection Fraction (LVEF) ≤35%

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

H.C.U de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain

Loading trial locations.

About this study

Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for SCD prevention in patients with non-ischemic dilated cardiomyopathy with LVEF≤35%

Randomization will be 1:1 and patients are allocated to either control strategy or intervention strategy.

In the control strategy group, patients will get an Implantable Cardioverter Defibrillator (ICD) implanted. Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a Dilated Cardiomyopathy DCM-causing pathogenic or likely pathogenic genetic variants or Late Gadolinium Enhancement (LGE) in Cardiac Magnetic Resonance (CMR). Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years at the time of screening.
  • Previously established diagnosis of Non-ischemic DCM
  • Optimised medical treatment at maximum tolerated doses for at least 3 months prior to the screening date.
  • NYHA functional class II-III.
  • LVEF ≤ 35% documented by CMR as study procedure.
  • Life expectancy greater than 12 months.

Exclusion criteria

  • History of coronary artery disease justifying the presence of ventricular dysfunction, defined as: history of coronary revascularisation or presence of significant coronary stenosis (≥50% in left main or ≥70% in a major epicardial artery) on invasive or non-invasive coronary angiography (coronary CT)
  • Left ventricular dysfunction attributed to congenital heart disease, valvular disease, alcohol abuse or chemotherapy.
  • Hypertrophic or infiltrative cardiomyopathy, active myocarditis or constrictive pericarditis.
  • History of recovered sudden death or sustained ventricular tachycardia.
  • NYHA functional class IV.
  • Waiting list for cardiac transplantation in emergency 0.
  • Receiver of a solid organ transplant (lung, liver, heart or kidney).

Treatment and study plan

Control Strategy

Other

ICDs will be implanted in all patients according to current recommendations

Personalized precision ICD implantation Strategy based in genetic findings and CMR results

Other

Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.

Primary outcomes

  1. Composite end-point of all cause death, hospitalization due to device-related complications, and non-fatal major arrhythmic events.

    Time frame: 4 years

Secondary outcomes

  1. All-cause death

    Time frame: 4 years

  2. SCD

    Time frame: 4 years

  3. Hospitalisation for device-related complications

    Time frame: 4 years

  4. Non-fatal major arrhythmic events

    Time frame: 4 years

  5. cost-effectiveness

    Time frame: 4 years

    Incremental Cost-effectiveness ratio (ICER) of personalized ICD allocation strategy in non-ischemic DCM [ Time Frame: The time horizon of the evaluation will be limited to 4 years ]

    The ICER of the personalized ICD allocation strategy compared with standard strategy is defined as the ratio between the variation in costs and the variation in effectiveness between both strategy groups. In the personalized strategy group, costs will include those related to personalization tests (CMR and genetic analysis) plus costs related to implanting and carrying an ICD (in the number of patients who eventually receive a device). In the control group, costs will include only the latter concept. Costs will be measured in Euros. The variation in effectiveness will be measured both in terms of life years gained, measured in years, and in terms of quality of life gained, measured in QALY. In the first case, ICER will be measured as Euros/year; in the second, it will be measured as Euros/QALY.

  6. Quality of life assessed by KCCQ, EQ-5D and HADS

    Time frame: 4 years

Study contacts

Contact information is provided by the study sponsor or research team.

Maria de la Iglesia

CONTACT

[email protected]

+34911916749

Projects Department (CIBER)

CONTACT

[email protected]

+34 91 822 28 74

Sponsors and collaborators

Lead sponsor

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Other Gov

Collaborators

  • Instituto de Salud Carlos III

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2027
First posted
Sep 26, 2023
Registry last updated
Feb 28, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.